Letermovir API
- Chemical Structure
- Chemical Details
- Mechanism of Action
- Manufacturing & Quality Control
CAS: 917389‑32‑3
Chemical Name:(4S)-8‑Fluoro‑2‑[4‑(3‑methoxyphenyl)piperazin-1-yl]‑3‑[2‑methoxy‑5‑(trifluoromethyl)phenyl]‑3,4-dihydro‑4‑quinazolinyl acetic acid
Molecular Weight: 572.6g
Molecular Formula: C₂₉H₂₈F₄N₄O₄
Physical Appearance: Off‑white to yellow solid powder (amorphous; slightly hygroscopic), insoluble in water and ethanol, but readily soluble in DMSO, DMF, acetonitrile, and acetone.
Letermovir is a selective antiviral medication that targets the cytomegalovirus (CMV) DNA terminase complex, primarily inhibiting the UL56 subunit, which is crucial for viral DNA cleavage and packaging. Its chemical structure is based on a quinazoline acetic acid derivative, enabling it to interfere with a unique step in CMV replication without affecting human DNA polymerases, thereby offering high specificity and reduced toxicity.
It is primarily used as a prophylactic antiviral agent to prevent cytomegalovirus (CMV) infection and disease in CMV-seropositive adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Letermovir's novel mechanism of action, distinct from DNA polymerase inhibitors, effectively halts the production of infectious CMV particles by disrupting viral DNA processing, thereby reducing the risk of CMV-related complications in immunocompromised patients.
Our Letermovir is manufactured under strict GMP conditions, ensuring the highest quality standards. The product undergoes rigorous quality control testing for identity, potency, purity, and safety before release.